# OnCo record evive-biotech (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/evive-biotech/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "evive-biotech" ;
  schema:name "Evive Biotech"@en ;
  schema:description "Evive Biotech developed efbemalenograstim alfa (Ryzneuta), a long-acting G-CSF fusion protein for chemotherapy-induced neutropenia approved in the US in 2023 and the EU in 2024."@en ;
  schema:url <https://onco.cc/companies/evive-biotech/>, <https://www.evivebiotech.com> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.evivebiotech.com> ;
  schema:addressCountry "CN" ;
  onco:drugs <https://onco.cc/drugs/efbemalenograstim-alfa/> ;
  onco:terms <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/febrile-neutropenia/> .